Cargando…

Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose

The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness of the complementary third dose. This was a prospective, longitudinal study in which we analyzed the kinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Biedunkiewicz, Bogdan, Tylicki, Leszek, Ślizień, Waldemar, Lichodziejewska-Niemierko, Monika, Dąbrowska, Małgorzata, Kubanek, Alicja, Rodak, Sylwia, Polewska, Karolina, Tylicki, Piotr, Renke, Marcin, Dębska-Ślizień, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950255/
https://www.ncbi.nlm.nih.gov/pubmed/35335065
http://dx.doi.org/10.3390/vaccines10030433
_version_ 1784675097108283392
author Biedunkiewicz, Bogdan
Tylicki, Leszek
Ślizień, Waldemar
Lichodziejewska-Niemierko, Monika
Dąbrowska, Małgorzata
Kubanek, Alicja
Rodak, Sylwia
Polewska, Karolina
Tylicki, Piotr
Renke, Marcin
Dębska-Ślizień, Alicja
author_facet Biedunkiewicz, Bogdan
Tylicki, Leszek
Ślizień, Waldemar
Lichodziejewska-Niemierko, Monika
Dąbrowska, Małgorzata
Kubanek, Alicja
Rodak, Sylwia
Polewska, Karolina
Tylicki, Piotr
Renke, Marcin
Dębska-Ślizień, Alicja
author_sort Biedunkiewicz, Bogdan
collection PubMed
description The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness of the complementary third dose. This was a prospective, longitudinal study in which we analyzed the kinetics of antibodies up to six months after a two-dose vaccination (first protocol) in infection-naïve dialysis patients (IN-Ds), previously infected dialysis patients (PI-Ds) and subjects without chronic kidney disease (the controls), as well as their humoral response to the third dose of the same mRNA vaccine (second protocol). The respective reduction in antibody titer after 3 and 6 months by 82.9% and 93.03% in IN-Ds (n = 109), 73.4% and 93.36% in PI-Ds (n = 32) and 75.5% and 88.8% in the controls (n = 20) was demonstrated. Consequently, a protective antibody titer above 141 BAU/mL was found in only 47.7% and 23.8% of IN-Ds after 3 and 6 months, respectively. After the third vaccine dose, a significant increase in antibody titer was observed in all groups, with increases by a factor of ×51.6 in IN-Ds, ×30.1 in the controls and ×8.4 in PI-Ds. The median antibody titer after the third dose differed significantly between groups, and was the highest in PI-Ds: PI-Ds, 9090 (3300–15,000) BAU/mL; the controls, 6945 (2130–11,800); IN-Ds, 3715 (1470–7325) (p < 0.001). In conclusion, we observed similar degrees of antibody waning in all patients. After 3 months, over half of the infection-naïve dialysis patients had a very low antibody titer, and almost twenty percent of them had no antibodies at all. The humoral response to the third dose was very good, raising their titer of antibodies to a higher level than those in the general population who have received the primary two-dose scheme. The results support the administration of a complementary third dose of the mRNA vaccine for dialysis patients as soon as possible.
format Online
Article
Text
id pubmed-8950255
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89502552022-03-26 Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose Biedunkiewicz, Bogdan Tylicki, Leszek Ślizień, Waldemar Lichodziejewska-Niemierko, Monika Dąbrowska, Małgorzata Kubanek, Alicja Rodak, Sylwia Polewska, Karolina Tylicki, Piotr Renke, Marcin Dębska-Ślizień, Alicja Vaccines (Basel) Article The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness of the complementary third dose. This was a prospective, longitudinal study in which we analyzed the kinetics of antibodies up to six months after a two-dose vaccination (first protocol) in infection-naïve dialysis patients (IN-Ds), previously infected dialysis patients (PI-Ds) and subjects without chronic kidney disease (the controls), as well as their humoral response to the third dose of the same mRNA vaccine (second protocol). The respective reduction in antibody titer after 3 and 6 months by 82.9% and 93.03% in IN-Ds (n = 109), 73.4% and 93.36% in PI-Ds (n = 32) and 75.5% and 88.8% in the controls (n = 20) was demonstrated. Consequently, a protective antibody titer above 141 BAU/mL was found in only 47.7% and 23.8% of IN-Ds after 3 and 6 months, respectively. After the third vaccine dose, a significant increase in antibody titer was observed in all groups, with increases by a factor of ×51.6 in IN-Ds, ×30.1 in the controls and ×8.4 in PI-Ds. The median antibody titer after the third dose differed significantly between groups, and was the highest in PI-Ds: PI-Ds, 9090 (3300–15,000) BAU/mL; the controls, 6945 (2130–11,800); IN-Ds, 3715 (1470–7325) (p < 0.001). In conclusion, we observed similar degrees of antibody waning in all patients. After 3 months, over half of the infection-naïve dialysis patients had a very low antibody titer, and almost twenty percent of them had no antibodies at all. The humoral response to the third dose was very good, raising their titer of antibodies to a higher level than those in the general population who have received the primary two-dose scheme. The results support the administration of a complementary third dose of the mRNA vaccine for dialysis patients as soon as possible. MDPI 2022-03-11 /pmc/articles/PMC8950255/ /pubmed/35335065 http://dx.doi.org/10.3390/vaccines10030433 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Biedunkiewicz, Bogdan
Tylicki, Leszek
Ślizień, Waldemar
Lichodziejewska-Niemierko, Monika
Dąbrowska, Małgorzata
Kubanek, Alicja
Rodak, Sylwia
Polewska, Karolina
Tylicki, Piotr
Renke, Marcin
Dębska-Ślizień, Alicja
Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title_full Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title_fullStr Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title_full_unstemmed Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title_short Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
title_sort waning humoral response after covid-19 mrna vaccination in maintenance dialysis patients and recovery after a complementary third dose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950255/
https://www.ncbi.nlm.nih.gov/pubmed/35335065
http://dx.doi.org/10.3390/vaccines10030433
work_keys_str_mv AT biedunkiewiczbogdan waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT tylickileszek waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT slizienwaldemar waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT lichodziejewskaniemierkomonika waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT dabrowskamałgorzata waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT kubanekalicja waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT rodaksylwia waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT polewskakarolina waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT tylickipiotr waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT renkemarcin waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose
AT debskaslizienalicja waninghumoralresponseaftercovid19mrnavaccinationinmaintenancedialysispatientsandrecoveryafteracomplementarythirddose